The impact of statin use on atrial fibrillation

QJM: An International Journal of Medicine

Volumn 101, Issue 11, 2008, Pages 845-861

  Sanchez Guinones J ^a   Marin F ^b   Roldan V ^c   Lip, G Y H ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

^d UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CARVEDILOL; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FENOFIBRATE; FISH OIL; FLUINDOSTATIN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; SPIRONOLACTONE; THROMBOPLASTIN; TRANDOLAPRIL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIARRHYTHMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARRHYTHMOGENESIS; CARDIOVERSION; CLINICAL TRIAL; DEFIBRILLATOR; DRUG USE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART SURGERY; HOSPITAL COST; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INFLAMMATION; MYOCARDITIS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERICARDITIS; PERIOPERATIVE PERIOD; PLEIOTROPY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

EID: 54949113715     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn101     Document Type: Review

References (132)

1. Go A, Hylek E, Phillips K, Henault L, Selby J, Singer D. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285 2370-5.
2. Benjamin E, Wolf P, D'Agostino R, Silbershatz H, Kannel W, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98:946-52.
3. Farré J. Seven reflections on a first episode of lone atrial fibrillation. Rev Esp Cardiol 2006; 59:1093-5.
4. Fuster V, Ryden L, Cannom D, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atriaA fibrillation): Full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2006; 48:854-906.
5. Shiroshita-Takeshita A, Brundel B, Nattel S. Atrial fibrillation: Basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 2005; 13:181-93.
6. Boos C, Anderson R, Lip G. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27:136-49.
7. Engelmann M, Svendsen J. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26:2083-92.
8. Boos C, Lip G. The role of inflammation in atrial fibrillation. Int J Clin Pract 2005; 59:870-2.
9. Dorian P. The future of atrial fibrillation therapy. J Cardiovasc Electrophysiol 2006; 17:S11-6.
10. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Do statins have an antiarrhythmic activity? Cardiovasc Res 2007; 75:10-20.
11. Tamargo J, Caballero R, Gómez R, Núñez L, Vaquero M, Delpón E. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol Ther 2007; 114:107-26.
12. Patel AA, White CM, Shah SA, Dale KM, Kluger J, Coleman CI. The relationship between statin use and atrial fibrillation. Curr Med Res Opin 2007; 23:1177-85.
13. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997; 96:157-63.
14. Bharti S, Lev M. Histology of the normal and diseased atrium. In: Fall RH, Podrid PJ, eds. Atrial Fibrillation: Mechanism and Management. New York, Raven Press, 1992:15-39.
15. Kistler P, Sanders P, Fynn S, Stevenson I, Spence S, Vohra J, et al Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol 2004; 44:109-16.
16. Nattel S. Atrial electrophysiology and mechanisms of atrial fibrillation. J Cardiovasc Pharmacol Therapeut 2003; 8(Suppl. 1):S5-11.
17. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovas Res 2005; 54 230.
18. Schoonderwoerd B, Van Gelder I, Van Veldhuisen D, Van den Berg M, Crijns H. Electrical and structural remodeling: Role in the genesis and maintenance of atrial fibrillation. Cardiovas Dis 2005; 48 153-68.
19. Wijffels M, Kirchhof C, Dorland R, Allessie M. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92:1954-68.
20. Yue L, Feng J, Gaspo R, Li G, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81:512-25.
21. Sun H, Chartier D, Leblanc N, Nattel S. Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res 2001; 49:751-61.
22. Kucera J, Rudy Y. Mechanistic insights into very slow conduction in branching cardiac tissue. A model study. Circ Res 2001; 89 799-806.
23. Frustaci A, Chimente C, Belloci F, Morgante E, Russo M, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-4.
24. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, et al Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90:400-5.
25. Libby P, Lee R. Matrix matters. Circulation 2000; 102:1874-6.
26. Li Y, McTieman C, Feldman A. Interplay os matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodelling. Cardiovasc Res 2000; 46:214-24.
27. Boixel C, Fontaine V, Rucker-Martin C, Milliez P, Louedec L, Michel JB, et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. Am J Cardiol 2003; 42:336-44.
28. Marín F, Rolán V, Climent V, García A, Marco P, Lip G. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 2003; 34 1181-6.
29. Mukherjee R, Herron A, Lowry A, Stroud RE, Stroud MR, Wharton JM, et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 2006; 97 532-7.
30. Schmieder R, Hilgers K, Schlaich M, Schmidt B. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369:1208-19.
31. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung T, Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003; 107:1930-6.
32. Elvan A, Pride H, Eble J, Zipes D. Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs. Circulation 1995; 91:2235-44.
33. Schauerte P, Scherlag B, Pitha J, Scherlag M, Reynolds D, Lazarra R. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 2000; 102:2774-80.
34. Iravanian S, Dudley S. Oxidative stress in the pathogenesis of atrial fibrillation. Curr Cardiol Rev 2006; 2:247-54.
35. Korantzopoulos P, Kolettis T, Galaris D, Goudevenos J. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007; 115:135-43.
36. Korantzopoulos P, Galaris D, Papaioannides D, Kokkoris S. C-reactive protein and oxidative stress in atrial fibrillation. Int J Cardiol 2003; 88:103-4.
37. Spodick D. Arrhythmias during acute pericarditis: A prospective study of 100 consecutive cases. JAMA 1976; 235:39-41.
38. Morgera T, Di Lenarda A, Dreas L, Pinamonti B, Humar F, Bussani R, et al. Electrocardiography of myocarditis revisited: Clinical and prognostic significance of electrocardiographic changes. Am Heart J 1992; 124:455-67.
39. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-43.
40. Ridker P. High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1313-8.
41. Morrow D, Rifai N, Antman E, Weiner DL, McCabe CH, Cannon CP, et al C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. Thrombolysis in myocardial infarction. J Am Coll Cardiol 1998; 31:1460-5.
42. Bruins P, Velthuis H, Yazdanbakhsh A, Jansen PG, van Hardevelt FW, de Beaumont EM, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997; 1997:3542-8.
43. Acevedo M, Corbalan R, Braun S, Pereira J, Navarrete C, González I. C-reactive protein and atrial fibrillation: 'evidence for the presence of inflammation in the perpetuation of the arrhythmia'. Int J Cardiol 2006; 108:326-31.
44. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006; 108:346-53.
45. Korantzopoulos P, Kolettis T, Kountouris E, Siogas L, Goudevenos J. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation: Is there an association with early recurrence rates? Int J Pract 2005; 59:881-5.
46. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104:2886-91.
47. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108:3006-10.
48. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, Stakos D, Floros D, Papanas N, et al. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 2006; 97:659-61.
49. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion. J Am Coll Cardiol 2007; 49:1642-8.
50. Psychari S, Apostolou T, Sinos L, Hamodraka E, Liakos G, Kremastinos D. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95:764-7.
51. Roldán V, Marín F, Blann A, García A, Marco P, Sogorb F, et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003; 24:1373-80.
52. Roldán V, Marín F, Martínez J, García-Herola A, Sogorb F, Lip G. Relation of interleukin-6 levels and prothrombin fragment 1 + 2 to a point-based score for stroke risk in atrial fibrillation. Am J Cardiol 2005; 2005:881-2.
53. Boos C, Lip G. The role of inflammation in atrial fibrillation: increasing evidence in support of a novel concept. Int J Clin Pract 2006; 60:495-9.
54. Mihm M, Yu F, Carnes C, Reiser PJ, McCarthy PM, Van Wagoner DR, et al Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104:174-80.
55. Dernellis J, Panaretou M. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am J Cardiol 2006; 97: 245-8.
56. Conway D, Buggins P, Hughes E, Lip G. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148:432-6.
57. Lip G, Patel J, Hughes E, Hart R. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007; 38:1229-37.
58. López B, Querejeta R, Varo N, González A, Larman M, Ubago J, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104 286-91.
59. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25:1100-7.
60. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: Potential mechanisms for atrial thrombosis and stroke. Circulation 2002; 160:2854-8.
61. Dudley S, Hoch N, McCann L, Honeycutt C, Diamandopoulos L, Fukai T, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: Role of the NADPH and xantihine oxidases. Circulation 2005; 112:1266-73.
62. Carnes C, Chung M, Nakayama T, Nakayama H, Baliga RS, Piao S, et al Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the icidence of postoperative atrial fibrillation. Circ Res 2001; 89:E32-8.
63. Kim Y, Guzik T, Zhang Y, Zhang M, Kattach H, Ratnatunga G. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005; 97:629-36.
64. Adam O, Frost G, Custodis F, Sussman MA, Schafers HJ, Bohm M, et al Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 2007; 50:359-67.
65. Kim Y, Lee J, Lim D, Shim WJ, Ro YM, Park GH, et al. Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp Mol Med 2003; 35:336-49.
66. Lin P, Lee S, Su C, Wei Y. Oxidative damage to mitochondrial DNA in atrial muscle of patients with atrial fibrillation. Free Radic Biol Med 2003; 35:1310-8.
67. Neuman RB, Bloom HL, Shukrullah I, Darrow LA, Kleinbaum D, Jones DP, et al. Oxidative markers are associated with persistent atrial fibrillation. Clin Chem 2007; 53:1652-7.
68. Grodos D, Tonglet R. Scandinavian simvastatin study (4S). Lancet 1994; 344:1768.
69. Waters D, Schawrtz G, Olsson A. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: A new frontier for statins? Curr Control Trials Cardiovasc Med 2001; 2:111-4.
70. Ross R. Atherosclerosis-An inflammatory disease. New Eng J Med 1999; 340:115-26.
71. Mora S, Ridker P. Justification for the use of statins in primary prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)-Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention? Am J Cardiol 2006; 97(Suppl):33A-41A.
72. Ridker P, Rifai N, Pfeffer M, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100:230-5.
73. Landsberger M, Wolff B, Jantzen F, Rosenstengel C, Vogelgesan D, Staudt A, et al. Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis 2007; 190:43-52.
74. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62 105-11.
75. Demellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005; 150 1064e7-e12.
76. García-Fernández A, Marín F, Mainar L, Roldán V, Martínez J. Effect of statins on preventing recurrence of atrial fibrillation alter electrical cardioversion. Am J Cardiol 2006; 98 1299-300.
77. Amar D, Zhang H, Heerdt P, Park B, Fleisher M, Thaler H. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 2005; 128:3421-7.
78. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455-61.
79. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004; 110 2313-9.
80. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 2005; 280:34202-9.
81. Maack C, Kartes T, Kilter H. Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and represents a target for statin treatment. Circulation 2003; 108:1567-74.
82. Crisby M, Nordin-Fredriksson G, Shah P, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metallo-proteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001; 103:926-33.
83. Rosenson R, Tangney C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279 1643-50.
84. Aikawa M, Rabkin E, Sugiyama S, Voglic S, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103:276-83.
85. Dupuis J, RTardif J, Cernacek P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99:3227-33.
86. Laufs U, La Fata V, Plutzky J, Liao J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97:1129-35.
87. Sundstrom J, Lind L, Vessby B, Andren B, Aro A, Lithell H. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation 2001; 103:836-41.
88. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105 868-73.
89. Lee TM, Lin MS, Chou TF, Tsai CH, Chang NC. Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 289 H220-7.
90. Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: Role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol 2002; 40:868-74.
91. Gao L, Wang W, Li Y, Schultz HD, Liu D, Cornish KG, et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: Roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005; 112:1763-70.
92. Pehlivanidis A, Athyros V, Demitriadis D, Papageorgiou A, Bouloukos V, Kontopoulos A. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157:463-9.
93. Vaquero M, Caballero R, Gómez R, Núñez L, Tamargo J, Delpón E. Effects of atorvastatin and simvastatin on atrial plateau currents. J Mol Cell Cardiol 2007; 42:931-45.
94. Tamargo J, Caballero R, Gómez R, Valenzuela C. Pharmacology of cardiac potassium channels. Cardiovasc Res 2004; 62:9-33.
95. Nerbonne J, Kass R. Molecular physiology of cardiac repolarization. Physiol Rev 2005; 85:1205-53.
96. Tang Q, Huang J, Qian H, Chen L, Wang T, Wang H, et al. Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization. Life Sci 2007; 80:601-8.
97. Lee T, Lin M, Tsai C, Chang N. Effects of pravastatin on ventricular remodeling by activation of myocardial KATP channels in infarcted rats: role of 70-kDa S6 kinase. Basic Res Cardiol 2007; 102:171-82.
98. Van der Linde N, Sijbrands E, Boomsma F. Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: A randomized trial with fluvastatin. Hypertension 2006; 47:1125-30.
99. Lozano H, Conde C, Florin T, Lamas G. Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy. Heart Rhythm 2005; 2:1000-7.
100. Healey J, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45:1834-9.
101. Merritt J, Niebauer M, Tarakji K, Hammer D, Mills R. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 2003; 92:735-6.
102. Cheruku K, Ghani A, Ahmad F, Pappas P, Silverman PR, Zelinger A, et al. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. Prev Cardiol 2004; 7:13-8.
103. Caló L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: A randomized, controlled trial. J Am Coll Cardiol 2005; 45:1723-8.
104. Shiroshita-Takeshita A, Brundrel B, Burstein B, Leung T, Mitamura H, Ogawa S, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007; 74:75-84.
105. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92:1379-83.
106. Dickinson M, Hellkamps A, Ip JH, Anderson J, Johnson GW, Singh SN, et al. Statin therapy was associated with reduced atrial fibrillation and flutter in heart failure patients in SCD-HeFT. Heart Rhythm 2006; 3(Suppl. 1):S49.
107. Hanna I, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3:881-6.
108. Adabag S, Nelson D, Bloomfield H. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 2007; 154:1140-5.
109. Merckx K, Tieleman R, Folkeringa R, Pinto YM, Nieman FH, Cheriez EC, et al. Use of statins is associated with reduced incidence of atrial fibrillation in patients with left ventricular hypertrophy and left atrial dilatation. Heart Rhythm Society 25th Annual Scientific Sessions. 28 May 2004, Abstract ID: 3669.
110. Malouf J, Kanagala R, Al Atawi F, Gabriela Rosales A. High sensitivity C-reactive protein A novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005; 46:1284-7.
111. Lombardi F, Colombo A, Basilico B, Ravaglia R, Garbin M, Vergani D, et al. Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion. J Am Coll Cardiol 2001; 37:157-62.
112. Mitchell L, Powell J, Gillis A, Kehl V, Hallstrom A, Investigators A. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003; 42:81-7.
113. Siu C, Lau C, Tse H. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92:1343-5.
114. Ozaydin M, Varol E, Aslan S, Kucuktepe Z, Dogan A, Ozturk M, et al Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97:1490-3.
115. Colivicchi F, Guido V, Ficili S, Mocini D, Ammirati F, Santini M. Effects of statin therapy on the recurrent of persistent atrial fibrillation in patients with essential hypertension: A propensity score-adjusted analysis. Eur Heart J 2004; 25(Suppl):S353.
116. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, et al Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004; 93:780-2.
117. Humphries K, Lee M, Sheldon R, Ramanathan K, Dorian P, Green M, et al Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 2007; 154:908-13.
118. Amit G, Katz A, Bar-On S, Gilutz H, Wagshal A, Ilia R, et al. Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker. Clin Cardiol 2006; 29 249-52.
119. Richter B, Derntl M, Marx M, Lercher P, Gossinger D. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: No effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007; 153:113-9.
120. Aranki S, Shaw D, Adams D, Rizzo RJ, Couper GS, VanderVliet M, et al Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation 1996; 94:390-7.
121. Ommen S, Odell J, Stanton M. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997; 336:1429-34.
122. Hogue CJ, Creswell L, Gutterman D, Fleisher L. American College of Chest Physicians. Epidemiology, mechanisms, and risks: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005; 128(Suppl. 2):9S-16S.
123. Abdelhadi R, Gurm H, Van Wagoner D, Chung M. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am J Cardiol 2004; 93:1176-8.
124. Fontes M, Mathew J, Rinder H, Zelterman D, Smith B, Rinder C. Atrial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation. Anesth Analg 2005; 101:17-23.
125. Gaudino M, Andreotti F, Zamparelli R, Di Castelnuovo A Nasso G, Burzotta F, et al. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation: Is atrial fibrillation an inflammatory complication? Circulation 2003; 108:195-9.
126. Brull D, Sanders J, Rumley A, Lowe GD, Humphries SE, Montgomer HE, et al. Statin therapy and the acute inflammatory response alter coronary artery bypass grafting. Am J Cardiol 2001; 88:431-3.
127. Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agrò F, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006; 34:660-7.
128. Durazzo A, Machado F, Ikeoka D, De Bernoche C, Monachini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: A randomized trial. J Vasc Surg 2004; 39:967-76.
129. Dotani M, Elnicki D, Jain A, Gibson C. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86:1128-30.
130. Ozaydin M, Dogan A, Varol E, Kapan S, Tuzun N, Peker O, et al. Statin use before the by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Am J Cardiol 2006; 97:1490-3.
131. Marín F, Pascual D, Roldán V, Arribas JM, Ahumada M, Tornel PL, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97:55-60.
132. Auer J, Weber T, Besent R, Lamm G, Ng CK, Hartl P, et al. Use of HMG-CoA reductase inhibitors and risk reduction of atrial fibrillation after cardiac surgery:AResults of the SPPAF study: a randomised placebo-controlled trial. Eur Heart J 2004; 25(Suppl.):353.